Arix Bioscience Plc - Management change
(“Arix”, LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces the departure of Chief Financial Officer, and promotion of Group Financial Controller, to Group Finance Director. These changes take place with immediate effect., :
, Chief Executive Officer commented:
“On behalf of the board I’d like to thank James for his contribution to Arix in the first stage of our development and wish him well in his future endeavours.”
For more information on Arix, please contact:
, Head of Investor Relations
+44 (0)20 7290 1072
+44 (0)203 950 9144
is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.
Quick facts: Arix Bioscience PLC
Market Cap: £117.3 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE